FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2023/09/057886 [Registered on: 20/09/2023] Trial Registered Prospectively
Last Modified On: 20/01/2025
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Other (Specify) [Mobile Application]  
Study Design  Other 
Public Title of Study   Assess the Impact of MyTatva Application in Management of Chronic Obstructive Pulmonary Disease. 
Scientific Title of Study   A Prospective, Randomized Controlled Trial to Assess the Impact of MyTatva Application in Management of Chronic Obstructive Pulmonary Disease. 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
Protocol No.: C2A03255 Version: 01 Date: 20 Jul 2023  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Dharmesh Domadia 
Designation  Vice President Global Clinical Operation 
Affiliation  Cliantha Research Limited 
Address  Cliantha Corporate, TP 86, FP 28/1, Off S.P. Ring Road, Sarkhej, Ahmedabad - 382 210, Gujarat, India

Ahmadabad
GUJARAT
382210
India 
Phone  919879590828  
Fax    
Email  ddomadia@cliantha.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Ankesh Barnwal 
Designation  Associate Director- I– Clinical Trial Medical Services 
Affiliation  Cliantha Research Limited 
Address  Cliantha Corporate, TP 86, FP 28/1, Off S.P. Ring Road, Sarkhej, Ahmedabad - 382 210, Gujarat, India

Ahmadabad
GUJARAT
382210
India 
Phone  07966219500  
Fax    
Email  abarnwal@cliantha.com  
 
Details of Contact Person
Public Query
 
Name  Mr Devesh Verma 
Designation  Associate Director-I - Clinical Trials 
Affiliation  Cliantha Research Limited 
Address  Cliantha Corporate, TP 86, FP 28/1, Off S.P. Ring Road, Sarkhej, Ahmedabad - 382 210, Gujarat, India

Ahmadabad
GUJARAT
382210
India 
Phone  919712908404  
Fax    
Email  dverma@cliantha.com  
 
Source of Monetary or Material Support  
Digicare Health Solutions Private Limited (formerly known as Digicare Healthcare Solutions Private Limited) 8th Floor, Astron Tower, Iscon Cross Road, Satellite Ahmedabad - 380015, Gujarat, India 
 
Primary Sponsor  
Name  Digicare Health Solutions Private Limited 
Address  8th Floor, Astron Tower, Iscon Cross Road, Satellite, Ahmedabad – 380 015, Gujarat, India 
Type of Sponsor  Other [Health care organization] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study
Modification(s)  
No of Sites = 7  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Agam Vora  Airway Clinic (Vora Clinic)  Airway Clinic (Vora Clinic), 3rd floor Mehul Building, LT Road, Sundar Nagar, Borivali (West), Mumbai – 400092, Maharashtra, India
Mumbai
MAHARASHTRA 
9820070054

dragamvora@gmail.com 
Dr Vijay Chennamchetty  Apollo Hospitals  Room No.2 Basement 1, International Block, Jubilee hills, Hyderabad - 500096, Telangana, India
Hyderabad
TELANGANA 
9701297721

drvizae@gmail.com 
Dr Kunjan Shah  Care and Cure Multispeciality Hospital  Besides Nilamkunj Society, Nr. Gokulnathji Haveli Mira Cinema Cross Road, Bhairavnath, Shah Alam Rd, Room A-101, 6th Floor, Maninagar, Ahmedabad - 380028, Gujarat, India
Ahmadabad
GUJARAT 
9428605404

kunjan7290@gmail.com 
Dr Leena Mistry  Charnock Hospital  Building No.4, OPD Section, Ground Floor, BMC 195, Teghoria, Biswas Bangla Sarani, Kolkata- 700157, West Bengal, India
Kolkata
WEST BENGAL 
9883304137

info@charnockhospital.com 
Dr Naveed Nazir Shah  Department of Pulmonary Medicine Govt. Chest Disease Hospital (G.M.C)  Ground Floor, Department of Pulmonary Medicine, Buchwara Dalgate, Srinagar, J&K, 190001, India
Srinagar
JAMMU & KASHMIR 
9419016438

naveednazirshah@yahoo.com 
Dr Jinesh Shah  Riddhi Medical Nursing Home  Clinical Research Room, A-101, Jalaram Plaza, Jawahar Chowk, Maninagar, Ahmedabad-380015, Gujarat, India
Ahmadabad
GUJARAT 
9879531832

drjinesh17@gmail.com 
Dr Jitendra Kotadiya  Zydus Hospitals & Healthcare Research Pvt Ltd  C Wing Zydus Hospital Road, S.G Highway, Clinical Research Room No. C21, 1st Floor, Clinical Research Department, Thaltej, Ahmedabad, 380054, Gujarat, India
Ahmadabad
GUJARAT 
9537045169

jitendrakotadiya@zydushospitals.com 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 7  
Name of Committee  Approval Status 
Charnock Ethics Committee  Approved 
Harmony Ethical Research Committee  Approved 
Institutional Ethics Committee  Approved 
Institutional Ethics Committee  Approved 
Riddhi Medical Nursing Home IEC  Approved 
Riddhi Medical Nursing Home IEC  Approved 
Zydus Hospital Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: J449||Chronic obstructive pulmonary disease, unspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  MyTatva mobile app plus Routine doctor advice plus Pharmacotherapy   The study duration will be around 12 weeks from randomization until end of study.  
Comparator Agent  Routine doctor advice plus Pharmacotherapy  The study duration will be around 12 weeks from randomization until end of study. 
 
Inclusion Criteria  
Age From  40.00 Year(s)
Age To  99.00 Year(s)
Gender  Both 
Details  Subject will be eligible for inclusion in this study only if all of the
following criteria apply:
1. Male or female patients >40 years of age with confirmed diagnosis of moderate to severe COPD as per GOLD guidelines with no exacerbations within last 12 months.
2. Patient having FEV1 ≥ 40% and ≤ 80% (without using bronchodilator) of the predictable value.
3. Patient is willing and able to provide written informed consent.
4. Patient is willing to comply with all study procedures and available for the duration of the study.
5. Patient with access to a smartphone with internet access.
6. Patient who will be able to use MyTatva App.
 
 
ExclusionCriteria 
Details  Subject will not be eligible for inclusion in this study if any of the
following criteria apply:
1. Persistent COPD with history of hospitalization in the last 6 months and unstable in the last 2 months.
2. Unable to read, write, or understand English.
3. The patient is not able to participate the exercise training program due to physical, cognitive or safety reasons, as judged by investigator, e.g., lower limb joint surgery within preceding 3 months, unstable cardiac disease, predominant neurological limitations and planned surgical or other interventions disturbing the study intervention.
4. Patient who is pregnant or planning to become pregnant.
5. Concurrent participation in any other interventional clinical trial.
6. Presumed or confirmed COVID-19 diagnosis within 30 days prior to randomization.
7. Co-existing known malignancy.
8. Patient not willing to perform coaching as instructed.
9. Patient with interstitial lung disease.
10. Severe exacerbations in last one month.
 
 
Method of Generating Random Sequence   Other 
Method of Concealment   Centralized 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Quality of life improvement (St. Georges Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT) questionnaire score), Improvement in functional capacity Six-minute walk test (6MWT), Percentage of patients with adherence to diet, exercise and medication (using questionnaire)

 
Change from baseline to Week 12
 
 
Secondary Outcome  
Outcome  TimePoints 
Improvement in lung function capacity – FEV1, FVC
Improvement in serum protein
Improvement in BMI
 
Change from baseline to Week 12 
 
Target Sample Size   Total Sample Size="100"
Sample Size from India="100" 
Final Enrollment numbers achieved (Total)= "104"
Final Enrollment numbers achieved (India)="104" 
Phase of Trial   Post Marketing Surveillance 
Date of First Enrollment (India)   08/12/2023 
Date of Study Completion (India) 23/01/2025 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="0"
Months="4"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Objective:

 

To evaluate the impact of lifestyle modification with diet and exercise delivered by MyTatva application in management of patients with chronic obstructive pulmonary disease (COPD).

 

Study Population:

 

In total, 100 patients will be included into trial, they will be randomized into either of the two arms with parallel group assignment in a 1:1 ratio.

 

Study Arms:

 

Intervention Arm- MyTatva mobile app + Routine doctor advice + Pharmacotherapy

Comparator Arm- Routine doctor advice + Pharmacotherapy

 

Clinical Evaluations :

The patients will be randomized to either of the below mentioned

two arms:

Intervention Arm (MyTatva application)

ï‚· All the details of the patient will be documented in the MyTatva App using Lifestyle Questionnaire form at screening/baseline/randomization.

 Quality of life improvement (St. George’s Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT) questionnaire score)

ï‚· The eligible patients meeting inclusion and exclusion criteria will receive customized diet and exercise plan based on the grading of the Lifestyle Questionnaire answered by them.

ï‚· The patients will receive regular recommendations or a standard of care provided through the investigator.

 

Comparator Arm

ï‚· All the details of the patient will be documented using the Lifestyle Questionnaire form at screening/baseline/randomization

 Quality of life improvement (St. George’s Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT) questionnaire score).

ï‚· The patients will receive regular recommendations or a standard of care provided through the Investigator. 6-minute walk test (6MWT) will be performed at site on baseline, every 4 weeks and 12 weeks for both the arms.

 Daily (Baseline to 12 weeks)

Steps count*, Calories burned of the calorie intake*, Sleep duration, heart rate*, sedentary time tracking*, SPO2*, FEV1** and FVC** will be examined on daily basis. AQI, humidity, Location temperature will be examine daily for intervention arm only.

*These activities will be a part of intervention arm only.

**FEV1 and FVC will be performed at site for comparator arm on baseline, every 4 weeks and 12 weeks visit.

 Every 2 weeks (±2 days)

ï‚· Physical activity intervention by exercise coach and diet intervention by diet coach will be examined every 2 weeks for intervention arm only. This activity will be carried out over the phone.

ï‚· Adverse Event Assessment.

 Every 4 weeks (±2 days/during interim visits)

ï‚· Vital signs (blood pressure, pulse rate, respiratory rate and body temperature), physical examination, 6MWT, FEV1, FVC and Body weight will be measure every 4 weeks.

ï‚· Adverse Event Assessment.

 At end of study (12 weeks (±4 days)) / Early termination visit

ï‚· Vital signs, Physical examination, Laboratory test (i.e. Serum protein & Vitamin D), Step Counts*, Sleep duration, Calories burned of the calorie intake*, Physical Activity Intervention by Exercise Coach*, 6 Minute walk test, Diet Intervention by Diet Coach*, Heart Rate*, Sedentary time tracking*, SpO2*, FEV1, FVC, Body weight, Body mass index (BMI), Patient satisfaction for MyTatva App (mHealth App Usability Questionnaire (MAUQ) )*

ï‚· Quality of life improvement will be evaluated by CAT questionnaire score and St. George Respiratory Questionnaire.

ï‚· Adverse Event Assessment

*These activities will be a part of intervention arm only.

Every 4 weeks (±2 days) will be during interim visits i.e. at 4 weeks and 8 weeks.

 
Close